VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 23, 2008) - Allon Therapeutics Inc. (TSX:NPC) today announced it has completed the randomized portion of its Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. The Company expects to release top-line results from this trial in the third quarter.
